Janssen Pharmaceutica Nv

Bayer Healthcare LLC

Ortho-mcneil Pharmaceutical Corp.

3-dimensional Pharmaceuticals, Inc.

Davoud Asgari

Mark R Player

Raymond Joseph Patch

Nand Baindur

Benjamin Brandt

Taxiarchis M Georgiadis

Naresh Chadha

Olaf Weber

Uday R Khire

Chunguang Wang

Mark Lynch

Jianxing Shao

Barry Hart

Xiao-Gao Liu

Carl R Illig

Dhanapalan Nagarathnam

Mark James Wall

Sanath K Meegalla

Jinsheng Chen

Stephen Boyer

Wing S Cheung

Jian Liu

Lei Wang

Lei Zhang

Donald Bankston

Dhanaphalan Nagarathnam

The invention is directed to compounds of Formula II: wherein A, R, R, R, R, X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

c-fms kinase inhibitors

Disclosed are compounds and derivatives thereof their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.

Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors

A process for the preparation of various quinazoline compounds which are useful as Rho-Kinase inhibitors, and thus having utility in the treatment of hypertension and other indications.

Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof

The invention is directed to compounds of Formulae I, II and III: wherein A, R, R, R, R, X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

C-fms kinase inhibitors

The invention is directed to compounds of Formulae I: wherein A, R, R, R, R, X, and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

The invention is directed to compounds of Formulae I and II: wherein R, R, R, R, R, Y, Y, Y, Yand X are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

Quinolinone derivatives as inhibitors of c-fms kinase

Growing community of inventors

Plainsboro, NJ, United States of America

Davoud Asgari